ID   WM35
AC   CVCL_0580
SY   WM-35; WM 35; WC00060
DR   BTO; BTO:0003475
DR   CLO; CLO_0009617
DR   MCCL; MCC:0000486
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2807
DR   BioSample; SAMN03471793
DR   cancercelllines; CVCL_0580
DR   Cell_Model_Passport; SIDM00974
DR   Coriell; WC00060
DR   Cosmic; 686396
DR   Cosmic; 886834
DR   Cosmic; 1155548
DR   Cosmic; 1187584
DR   Cosmic; 1247866
DR   Cosmic; 1303075
DR   Cosmic; 1507600
DR   Cosmic; 1995666
DR   Cosmic; 2159431
DR   Cosmic-CLP; 1299080
DR   DepMap; ACH-002207
DR   EGA; EGAS00001000978
DR   GDSC; 1299080
DR   GEO; GSM109040
DR   GEO; GSM186484
DR   GEO; GSM186485
DR   GEO; GSM188068
DR   GEO; GSM188120
DR   GEO; GSM188193
DR   GEO; GSM188208
DR   GEO; GSM188213
DR   GEO; GSM188284
DR   GEO; GSM188293
DR   GEO; GSM555119
DR   GEO; GSM555188
DR   GEO; GSM952586
DR   GEO; GSM1670580
DR   LINCS_LDP; LCL-1263
DR   Lonza; 583
DR   PharmacoDB; WM35_1672_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0580
DR   Wikidata; Q54994256
RX   PubMed=2068080;
RX   PubMed=2253310;
RX   PubMed=8160777;
RX   PubMed=11123321;
RX   PubMed=16827748;
RX   PubMed=18632627;
RX   PubMed=18790768;
RX   PubMed=23039341;
RX   PubMed=27087056;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://web.archive.org/web/20141129125241/http://www.wistar.org:80/lab/meenhard-herlyn-dvm-dsc/page/melanoma-cell-lines-0
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=18632627; Cosmic-CLP; DepMap; Wistar).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0.26%; East Asian, South=0.38%; South Asian=0.25%; European, North=72.7%; European, South=26.42% (PubMed=30894373).
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: D18S51: 20->14,15 and FGA: 19->19,24.
CC   Discontinued: ATCC; CRL-2807; true.
CC   Discontinued: Coriell; WC00060; probable.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=27087056; Wistar
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 12,13
ST   D18S51: 14,15
ST   D19S433: 15,16
ST   D21S11: 29,32.2
ST   D2S1338: 18,25
ST   D3S1358: 16,18
ST   D5S818: 11,12
ST   D7S820: 10,13
ST   D8S1179: 11,13
ST   FGA: 19,24
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   24Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 32
//
RX   PubMed=2068080; DOI=10.1073/pnas.88.14.6028;
RA   Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A.,
RA   Kerbel R.S.;
RT   "Fibroblast cell interactions with human melanoma cells affect tumor
RT   cell growth as a function of tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991).
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=8160777;
RA   Kobayashi H., Man S., MacDougall J.R., Graham C.H., Lu C.,
RA   Kerbel R.S.;
RT   "Variant sublines of early-stage human melanomas selected for
RT   tumorigenicity in nude mice express a multicytokine-resistant
RT   phenotype.";
RL   Am. J. Pathol. 144:776-786(1994).
//
RX   PubMed=11123321; DOI=10.4049/jimmunol.166.1.432;
RA   Li J., Pereira S., Van Belle P., Tsui P., Elder D.E., Speicher D.W.,
RA   Deen K., Linnenbach A., Somasundaram R., Swoboda R.K., Herlyn D.;
RT   "Isolation of the melanoma-associated antigen p23 using antibody phage
RT   display.";
RL   J. Immunol. 166:432-438(2001).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431;
RA   Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B.,
RA   Egyhazi Brage S., Hansson J., Wu H., King A.J., Van Belle P.,
RA   Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.;
RT   "Increased cyclin D1 expression can mediate BRAF inhibitor resistance
RT   in BRAF V600E-mutated melanomas.";
RL   Mol. Cancer Ther. 7:2876-2883(2008).
//
RX   PubMed=23039341; DOI=10.1186/1476-4598-11-75;
RA   Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J.,
RA   Nomoto K., Pollock P.M.;
RT   "Sensitivity to the MEK inhibitor E6201 in melanoma cells is
RT   associated with mutant BRAF and wildtype PTEN status.";
RL   Mol. Cancer 11:75.1-75.15(2012).
//
RX   PubMed=27087056; DOI=10.1038/srep24569;
RA   Haridas P., McGovern J.A., Kashyap A.S., McElwain D.L.S., Simpson M.J.;
RT   "Standard melanoma-associated markers do not identify the MM127
RT   metastatic melanoma cell line.";
RL   Sci. Rep. 6:24569-24569(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//